The investment manager sold $5.1 million worth of LQDA stock, according to its most recent SEC filing.

Prev Article Next Article

Opaleye Management Inc. In an SEC filing on February 17, 2026, it disclosed that it had sold 180,000 shares. liquid (NASDAQ:LQDA)an estimated trade of $5.12 million based on the quarterly average price.

According to an SEC filing on February 17, 2026, Opaleye Management Inc. Sold 180,000 shares of Liquidia stock in 2025 Q4. The estimated business value was approximately $5.12 million, based on the average closing price for the quarter. The fund ended the period with 2,435,000 shares, a quarter-end value increase of $25.52 million due to both trading activity and stock appreciation.

Opaleye Management Inc. Reduced its Liquidia position, which now accounts for 11.21% of reportable AUM.

Top properties after filing:

NASDAQ:HROW: $191.34 million (25.2% of AUM)
NASDAQ:LQDA: $84.98 million (11.2% of AUM)
NASDAQ: ETON: $48.36 million (6.4% AUM)
NASDAQ: RYTM: $35.32 million (4.7% of AUM)
NASDAQ:APGE: $29.31 million (3.9% of AUM)

As of February 17, 2026, the stock was trading at $33.84, up 105.7% from last year, compared to 97.0 percentage points above the S&P 500.

Matric	value
Price (as of market close 2/17/26)	$33.84
Market capitalization	2.94 billion dollars
Revenue (TTM)	69.22 million dollars
net income (TTM)	($121.85 million)

Products include YUTREPIA, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension, and distribution of generic treprostinil injection in the United States.
Revenue is generated primarily through the development, manufacture, and commercialization of proprietary and generic therapies that target unmet needs in pulmonary arterial hypertension.
The company targets healthcare providers and patients in the United States who need advanced treatments for pulmonary arterial hypertension and related conditions.

Liquidia is a biopharmaceutical company focused on innovative treatments for pulmonary arterial hypertension, leveraging proprietary drug delivery technologies. The company’s strategy focuses on addressing unmet medical needs through various product formulations and expanding its portfolio in the US market. Liquidia’s competitive advantage lies in its specialized expertise in respiratory drug delivery and its ability to commercialize both branded and generic therapies in a highly regulated sector.

Opaleye Management, a Massachusetts-based investment manager, recently disclosed the sale of Liquidia stock worth approximately $5.1 million. Here’s how investors like to think about it.

First, Liquidia is a drug store. The company focuses on the treatment of hypertension (high blood pressure). In particular, the company makes inhalable drugs for the treatment of diseases.

Overall, the landscape of the pharmaceutical industry is very complex. There are big and small players, and not just in private industry. The sector is highly regulated, both in terms of drug approvals by the Food and Drug Administration (FDA), and in terms of insurance reimbursement, overseen by private insurers and government agencies.

In other words, this sector can be very difficult for retail investors to navigate. Therefore, in my opinion, the pharmaceutical sector is the perfect area for the average investor to turn to exchange traded funds (ETFs).

By giving them exposure to a broad range of stocks in the industry, biotech, pharmaceutical, and healthcare ETFs offer investors some protection against over-concentration in a single company whose products could be the victim of regulatory disruption or an adverse coverage decision by a major insurance or government program.

Before you buy stock in Liquidia, consider this:

of the Motley Fool Stock Advisor The analyst team identified only what they believed 10 best stocks For investors to buy now…and Levidia was not one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix This list was created on December 17, 2004 … If you invested $1,000 at the time of our recommendation, You will have $526,889or when Nvidia This list was created on April 15, 2005 … If you invested $1,000 at the time of our recommendation, You will have $1,103,743!*

Now, this is significant Stock consultant The total average return is 947% – Outperformed the market by 192% for the S&P 500. Don’t miss the latest Top 10 list, available with Stock consultantand join an investment community created by individual investors for individual investors.

View 10 Stocks »

* Stock Advisor returns to March 4, 2026.

Jack Leach has no position in any of the listed stocks. The Motley Fool has and recommends positions in Rhythm Pharmacy. Motley Fool has a disclosure policy.

Investment manager sells $5.1 million worth of LQDA stock, according to latest SEC filing Originally published by The Motley Fool

Click Here to Get More